# T2 Biosystems

its T2Resistance Panel uses magnetic-resonance-based detection to identify antibiotic-resistance genes directly from blood without waiting for culture, continuing to publish clinical-benefit data and advance its product pipeline.

Source: https://en.bioecon.ru/companies/t2-biosystems/
Updated: 2026-07-20

- Country: United States
- Ticker: TTOO

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | $7.2 million (2023-12-31) | https://www.sec.gov/Archives/edgar/data/1492674/000119312524262578/d887064dars.pdf |
| Revenue | $8.3 million in product revenue (2024-12-31) | https://www.sec.gov/Archives/edgar/data/1492674/000119312525002629/d885819dex991.htm |
| Headcount | 113 employees (2023-12-31) | https://www.macrotrends.net/stocks/charts/TTOO/t2-biosystems/number-of-employees |
| Production site | Lexington, Massachusetts and Wilmington, Massachusetts | https://investors.t2biosystems.com/static-files/4e176faa-fc76-4468-9428-51263085026b, https://t2biosystems.gcs-web.com/static-files/4e176faa-fc76-4468-9428-51263085026b, https://www.sec.gov/Archives/edgar/data/1492674/000119312524262578/d887064dars.pdf |
| Certification | ISO 13485:2016 certification | https://www.sec.gov/Archives/edgar/data/1492674/000119312524262578/d887064dars.pdf |
| Regulatory approval | CE marked in the EU for the T2Resistance Panel; FDA Breakthrough Device designation granted for the U.S. T2Resistance Panel | https://carb-x.org/wp-content/uploads/2024/02/T2-Biosystems-T2Resistance-Panel-Stewardship-and-Access-Plan.pdf, https://www.sec.gov/Archives/edgar/data/1492674/000119312519296088/d838072dex991.htm, https://www.sec.gov/Archives/edgar/data/1492674/000119312524262578/d887064dars.pdf |
| Capacity | Facilities in Lexington and Wilmington, Massachusetts are considered adequate for current manufacturing needs with additional space available for expansion | https://investors.t2biosystems.com/static-files/4e176faa-fc76-4468-9428-51263085026b, https://t2biosystems.gcs-web.com/static-files/4e176faa-fc76-4468-9428-51263085026b, https://www.sec.gov/Archives/edgar/data/1492674/000119312524262578/d887064dars.pdf |
| Funding | $2.0 million from CARB-X in 2017; milestone-based contract with BARDA with an initial value of $6 million and potential value up to $69 million | https://carb-x.org/carb-x-news/t2-biosystems-t2resistance-panel-is-first-diagnostic-to-graduate-from-carb-x-portfolio/, https://t2biosystems.gcs-web.com/news-releases/news-release-details/t2-biosystems-t2resistancetm-panel-first-diagnostic-graduate, https://www.sec.gov/Archives/edgar/data/1492674/000119312524262578/d887064dars.pdf |

Independent sources: carb-x.org, macrotrends.net, sec.gov

## Technologies

- [Rapid antibiotic-resistance tests](https://en.bioecon.ru/technology/rapid-antibiotic-resistance-tests/)